DOCSLIB.ORG

High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity Western Michigan University ScholarWorks at WMU Dissertations Graduate College 5-2010 High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity Albert A. Barrese III Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biochemistry, Biophysics, and Structural Biology Commons, and the Biology Commons Recommended Citation Barrese, Albert A. III, "High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity" (2010). Dissertations. 500. https://scholarworks.wmich.edu/dissertations/500 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. HIGH-THROUGHPUT SCREENING STUDIES OF INHIBITION OF HUMAN CARBONIC ANHYDRASE II AND BACTERIAL FLAGELLA ANTIMICROBIAL ACTIVITY by Albert A. Barrese III A Dissertation Submitted to the Faculty of The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Biological Sciences Advisor: Brian C. Tripp, Ph.D. Western Michigan University Kalamazoo, Michigan May 2010 UMI Number: 3410393 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. UMT Dissertation Publishing UMI 3410393 Copyright 2010 by ProQuest LLC. All rights reserved. This edition of the work is protected against unauthorized copying under Title 17, United States Code. uest ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 HIGH-THROUGHPUT SCREENING STUDIES OF INHIBITION OF HUMAN CARBONIC ANHYDRASE II AND BACTERIAL FLAGELLA ANTIMICROBIAL ACTIVITY Albert A. Barrese III, Ph.D. Western Michigan University, 2010 Carbonic anhydrase (CA) enzymes catalyze the reversible hydration of carbon dioxide to form bicarbonate and release a proton. There are currently five known CA structural families, a-, p-, y-, 5-, and ^-classes, as reviewed in Chapter One. In Chapter Two, the hypothesis that a high-throughput screen (HTS) of diverse biologically active compounds could yield new structural insights into CA inhibition and identify new inhibitors for this enzyme was experimentally tested. Human CA II was screened against 960 structurally diverse, biologically active small molecules. The assay monitored CA II esterase activity against the substrate 4- nitrophenyl acetate (4-NPA) in a format allowing high-throughput screening. The assay proved to be robust and reproducible with a hit rate of <2%. Chapter Three examines the functional mechanism of thioxolone. Analytical chemistry and biochemical methods were used to investigate the fate of thioxolone upon binding to CA II. When thioxolone binds in the active site of CA II it is cleaved and forms 4-mercaptobenzene-l,3-diol which then binds to the zinc active site via the thiol group, and is therefore the active CA inhibitor. The preliminary development and validation of a novel methodology for the high-throughput screening of antimicrobial compounds and inhibitors of bacterial motility is described in Chapter Four. Two basic techniques were combined to enable rapid screening for motility inhibitors; the classical bacterial swarming agar motility assay and the use of 96-well microplates common to HTS drug discovery techniques with a standard absorbance microplate reader. The feasibility of screening the Salmonella typhimurium SJW1103 strain, which is wild-type for flagellar motility and has peritrichously arranged flagella, was examined. The non-physiological substrate, 4-nitrophenyl acetate, does not react with all known isozymes of a-class CAs or the y-class CA from M. thermophila. Preliminary studies describing the subcloning and expression CA I and a truncated, soluble form of CA IV, are described in Chapter Five. This chapter also details the preliminary exploration of several alternative pH absorbance assays for measuring the catalytic activity of CAs. Finally, some possible directions for future research, based on the experimental results presented in Chapters 2-5, are discussed in Chapter Six. Copyright by Albert A. Barrese III 2010 ACKNOWLEDGMENTS I would like to thank Dr. Tripp for his guidance, support, dedication and patience with me during my graduate study at Western Michigan University. He was a great mentor and I feel that the skills that I learned from him will start my scientific career off in a successful way. I would also like to thank my committee members; Dr. John Geiser, Dr. James Kiddle, and Dr. Wendy Ransom-Hodgkins. Their suggestions and thoughtful insights have given me the opportunity to critically think about my work and at times see a new direction for my work to proceed in. Lastly I would like thank my family and friends for their support and patience without them this work would not have been possible. Albert A. Barrese III ii TABLE OF CONTENTS ACKNOWLEDGMENTS ii LIST OF TABLES vii LIST OF FIGURES ix CHAPTER I. OVERVIEW OF CARBONIC ANHYDRASE ENZYMES, INHIBITORS, AND BACTERIAL FLAGELLIN PROTEINS 1 Introduction 1 Carbonic Anhydrase Enzyme Classification, Protein Structures, and Catalytic Mechanisms 1 Inhibitors of Carbonic Anhydrase 15 Medical Applications of Carbonic Anhydrase Inhibitors 17 Bacterial Flagellin Protein 19 References 25 II. CA II INHIBITION STUDIES WITH THE GENESIS PLUS AND NCI DIVERSITY SET COMPOUND LIBRARIES 37 Introduction 37 Experimental Procedures 38 Compound Libraries 39 Esterase Activity Screening Assay 41 Inhibitor IC50 Measurement 42 iii Table of Contents-Continued CHAPTER Inhibitor Kd Measurement 45 Results 47 GenPlus Compound Library: Preliminary Identification of Hits 47 Reproducibility 55 Signal to Noise Characteristics 57 Enzyme and Substrate Stability 59 Hit Confirmation 60 I. Sulfonamide CAIs 60 II. Non-Sulfonamide CAIs 63 Hit Characterization 67 Results of IC50 Assays with 1 uM CA II 68 Results of IC50 Assay with 5 uM CA II 68 Hill Slope as an Indicator of Promiscuity 69 Results of IC50 Assay with 1 uM CA II and Triton X-100 70 Dissociation Constant Assay Results 72 Comparison of IC50 and Kd Values 77 NCI Compound Library 79 Discussion 90 iv Table of Contents-Continued CHAPTER Limitations of 4-NPA Esterase Assay 90 Esterase vs. Fluorescence Screening Assays 92 References 94 III. MECHANISTIC STUDIES OF HUMAN CARBONIC ANHYDRASE II INHIBITION BY THIOXOLONE 101 Introduction 101 Experimental Procedures 104 Enzyme Expression and Purification 104 Materials 106 Preparation of 4-mercaptobenzene-l,3-diol (Compound 3) by acid hydrolysis of thioxolone (Compound 1) 106 Carbonic Anhydrase 4-NPA Esterase Inhibition Studies 109 Michaelis-Menten Enzyme Kinetic Studies 110 Liquid Chromatography-Mass Spectroscopic Studies 113 Results 115 Structure-Activity Relationship Study 115 Enzyme Kinetic Studies 129 Liquid Chromatography-Mass Spectroscopy Analysis of Thioxolone and Hydrolysis Products 136 Discussion 138 References 143 v Table of Contents-Continued CHAPTER IV. A HIGH-THROUGHPUT SCREENING ASSAY FOR DETECTING INHIBITION OF FLAGELLAR MOTILITY 148 Introduction 148 Experimental Procedures 149 Results and Discussion 152 References 166 V. CARBONIC ANHYDRASE SUBCLONING, EXPRESSION, AND C02 HYDRATION ACTIVITY ASSAY DEVELOPMENT... 168 Carbonic Anhydrase Isozyme Subcloning and Expression 168 Expression and Purification of y-class Carbonic Anhydrase (Cam) 192 Sodium Bicarbonate pH Assay 196 References 217 VI. FUTURE WORK 219 Reference 224 APPENDIX Recombinant DNA Biosafety Approval 225 vi LIST OF TABLES 2.1. Potential carbonic anhydrase II inhibitor compounds identified in initial screen of Genesis Plus compound library, as confirmed by two statistical criteria 49 2.2. Summary of IC50 values and K& values for Genesis Plus hit compounds and model sulfonamide compounds 74 2.3 Carbonic anhydrase II inhibitor compounds identified in a screen of the NCI Diversity set compound library 83 3.1. Structures and apparent IC50 values for inhibition of human carbonic anhydrase II by thioxolone analogs 119 3.2. Michaelis-Menten kinetic parameters determined for concentration- dependence of thioxolone inhibition of 4-nitrophenyl acetate hydrolysis by carbonic anhydrase II 131 3.3. Mechanism-based enzyme inactivation parameters determined for thioxolone inhibition of 4-nitrophenyl acetate hydrolysis by carbonic anhydrase II 136 4.1. Complete list of antibacterial compounds detected in screen of Genesis Plus library with offset motility detection method 161 5.1. Mammalian a-class carbonic anhydrase clone vector and sequence information 170 5.2. Sequencing results for the pET28c-CA I and pET28c-CA IV 176 5.3. Partial blastx search results with CA I DNA sequence results 177 5.4. Partial blastx search results with CA IV DNA sequence results 178 5.5. The translated peptide sequence for the subcloned carbonic anhydrase I and IV genes in the pET 28c-CA I and pET 28c-CA IV plasmids 179 vii List of Tables-Continued 5.6. Comparison of the translated CA I pET28c-CA I plasmid DNA sequence to the wild-type protein sequence 180 5.7. Comparison of pEt 28c-CA I V plasmid DNA sequence to the wild-type CA IV sequence 181 5.8. Results of non-linear fit of standard CA II esterase assay IC50 data using Graph Pad Prism 4.0 sigmoidal dose-response model/curve fit 206 5.9. Results of non-linear fit for microplate format CA II CO2 hydration pH assay IC50 data using Graph Pad Prism 4.0 sigmoidal dose-response model/curve fit 206 5.10. Statistical results of fluorescein MultiDrop 8-channel peristaltic test for three successive dispensing operations into 96-well microplates 209 5.11. The concentration of reagents right after mixing the aqueous solution of sulphuric acid, cobalt sulphate, and potassium dihydrogen phosphate with an aqueous solution of sodium bicarbonate 210 5.12. CA II carbonic acid dehydrating to CO2 pH assay.
Load more

Recommended publications
  • Association Analyses of Known Genetic Variants with Gene
    ASSOCIATION ANALYSES OF KNOWN GENETIC VARIANTS WITH GENE EXPRESSION IN BRAIN by Viktoriya Strumba A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Bioinformatics) in The University of Michigan 2009 Doctoral Committee: Professor Margit Burmeister, Chair Professor Huda Akil Professor Brian D. Athey Assistant Professor Zhaohui S. Qin Research Statistician Thomas Blackwell To Sam and Valentina Dmitriy and Elizabeth ii ACKNOWLEDGEMENTS I would like to thank my advisor Professor Margit Burmeister, who tirelessly guided me though seemingly impassable corridors of graduate work. Throughout my thesis writing period she provided sound advice, encouragement and inspiration. Leading by example, her enthusiasm and dedication have been instrumental in my path to becoming a better scientist. I also would like to thank my co-advisor Tom Blackwell. His careful prodding always kept me on my toes and looking for answers, which taught me the depth of careful statistical analysis. His diligence and dedication have been irreplaceable in most difficult of projects. I also would like to thank my other committee members: Huda Akil, Brian Athey and Steve Qin as well as David States. You did not make it easy for me, but I thank you for believing and not giving up. Huda’s eloquence in every subject matter she explained have been particularly inspiring, while both Huda’s and Brian’s valuable advice made the completion of this dissertation possible. I would also like to thank all the members of the Burmeister lab, both past and present: Sandra Villafuerte, Kristine Ito, Cindy Schoen, Karen Majczenko, Ellen Schmidt, Randi Burns, Gang Su, Nan Xiang and Ana Progovac.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • Quantigene Flowrna Probe Sets Currently Available
    QuantiGene FlowRNA Probe Sets Currently Available Accession No. Species Symbol Gene Name Catalog No. NM_003452 Human ZNF189 zinc finger protein 189 VA1-10009 NM_000057 Human BLM Bloom syndrome VA1-10010 NM_005269 Human GLI glioma-associated oncogene homolog (zinc finger protein) VA1-10011 NM_002614 Human PDZK1 PDZ domain containing 1 VA1-10015 NM_003225 Human TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) VA1-10016 NM_002276 Human KRT19 keratin 19 VA1-10022 NM_002659 Human PLAUR plasminogen activator, urokinase receptor VA1-10025 NM_017669 Human ERCC6L excision repair cross-complementing rodent repair deficiency, complementation group 6-like VA1-10029 NM_017699 Human SIDT1 SID1 transmembrane family, member 1 VA1-10032 NM_000077 Human CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) VA1-10040 NM_003150 Human STAT3 signal transducer and activator of transcripton 3 (acute-phase response factor) VA1-10046 NM_004707 Human ATG12 ATG12 autophagy related 12 homolog (S. cerevisiae) VA1-10047 NM_000737 Human CGB chorionic gonadotropin, beta polypeptide VA1-10048 NM_001017420 Human ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) VA1-10050 NM_197978 Human HEMGN hemogen VA1-10051 NM_001738 Human CA1 Carbonic anhydrase I VA1-10052 NM_000184 Human HBG2 Hemoglobin, gamma G VA1-10053 NM_005330 Human HBE1 Hemoglobin, epsilon 1 VA1-10054 NR_003367 Human PVT1 Pvt1 oncogene homolog (mouse) VA1-10061 NM_000454 Human SOD1 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))
    [Show full text]
  • An Update on the Metabolic Roles of Carbonic Anhydrases in the Model Alga Chlamydomonas Reinhardtii
    H OH metabolites OH Review An Update on the Metabolic Roles of Carbonic Anhydrases in the Model Alga Chlamydomonas reinhardtii Ashok Aspatwar 1,* ID , Susanna Haapanen 1 and Seppo Parkkila 1,2 1 Faculty of Medicine and Life Sciences, University of Tampere, FI-33014 Tampere, Finland; [email protected].fi (S.H.); [email protected].fi (S.P.) 2 Fimlab, Ltd., and Tampere University Hospital, FI-33520 Tampere, Finland * Correspondence: [email protected].fi; Tel.: +358-46-596-2117 Received: 11 January 2018; Accepted: 10 March 2018; Published: 13 March 2018 Abstract: Carbonic anhydrases (CAs) are metalloenzymes that are omnipresent in nature. − + CAs catalyze the basic reaction of the reversible hydration of CO2 to HCO3 and H in all living organisms. Photosynthetic organisms contain six evolutionarily different classes of CAs, which are namely: α-CAs, β-CAs, γ-CAs, δ-CAs, ζ-CAs, and θ-CAs. Many of the photosynthetic organisms contain multiple isoforms of each CA family. The model alga Chlamydomonas reinhardtii contains 15 CAs belonging to three different CA gene families. Of these 15 CAs, three belong to the α-CA gene family; nine belong to the β-CA gene family; and three belong to the γ-CA gene family. The multiple copies of the CAs in each gene family may be due to gene duplications within the particular CA gene family. The CAs of Chlamydomonas reinhardtii are localized in different subcellular compartments of this unicellular alga. The presence of a large number of CAs and their diverse subcellular localization within a single cell suggests the importance of these enzymes in the metabolic and biochemical roles they perform in this unicellular alga.
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Extracts from PRAC Recommendations on Signals Adopted at the 9-12 March 2020 PRAC
    6 April 20201 EMA/PRAC/111218/2020 Corr2,3 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording – Extracts from PRAC recommendations on signals Adopted at the 9-12 March 2020 PRAC The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through. 1. Immune check point inhibitors: atezolizumab; cemiplimab; durvalumab – Tuberculosis (EPITT no 19464) IMFINZI (durvalumab) Summary of product characteristics 4.4. Special warnings and precautions for use Immune-mediated pneumonitis [..] Patients with sSuspected pneumonitis should be evaluated confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2. LIBTAYO (cemiplimab) Summary of product characteristics 1 Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals. 2 A footnote was deleted on 8 April 2020 for the signal on thiazide and thiazide-like diuretics (see page 3). 3 A minor edit was implemented in the product information of the signal on thiazide and thiazide-like diuretics on 5 June 2020 (see page 4). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Table S1. Detailed Clinical Features of Individuals with IDDCA and LADCI Syndromes
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Med Genet Table S1. Detailed clinical features of individuals with IDDCA and LADCI syndromes Lodder E., De Nittis P., Koopman C. et al., 2016 Family A Family B Family C Family D Family E Family F Individual 1 2 3 4 5 6 7 8 9 Gender, Age (years) F, 22 F, 20 F, 6 F, 11 M, 9 F, 12 F, 13 M, 8 M, 23 c.249G>A,r.249_250 c.249G>A,r.249_250 Nucleotide change c.249+1G>T/ c.249+3G>T/ c.249+3G>T/ c.906C>G/ c.242C>T/ c.242C>T/ c.242C>T/ ins249+1_249+25/ ins249+1_249+25/ (NM_006578.3) c.249+1G>T c.249+3G>T c.249+3G>T c.906C>G c.242C>T c.242C>T c.242C>T c.994C>T c.994C>T Amino acid change p.Asp84Valfs*52/ p.Asp84Valfs*52/ p.Asp84Leufs*31/ p.Asp84Valfs*31/ p.Asp84Valfs*31/ p.Tyr302*/ p.(Ser81Leu)/ p.(Ser81Leu)/ p.(Ser81Leu)/ (NP_006569.1) p.(Arg332*) p.(Arg332*) p.Asp84Leufs*31 p.Asp84Valfs*31 p.Asp84Valfs*31 p.Tyr302* p.(Ser81Leu) p.(Ser81Leu) p.(Ser81Leu) 3580 g (50th 2751 g (15 th Birth weight NA NA NA 2845 g (15th NA NA NA percentile) percentile) percentile) Ethnicity Italy Italy Jordan Puerto Rico Puerto Rico India Morocco Morocco Brazil Consanguinity − − + + + − − − + Altered speech + + NR + + + + + NA development - Verbal NA NA nonverbal unremarkable unremarkable NA NA NA NA understanding - Lexical production NA NA nonverbal delayed delayed nonverbal delayed delayed NA Intellectual + + + + + + mild mild mild disability (ID) Epilepsy + + + -
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pdf (329.48 K)
    Bull. Pharm. Sci., Assiut University, Vol. 29, Part 1, June 2006, pp. 33-58. SPECTROPHOTOMETRIC AND SPECTRO- FLUORIMETRIC DETERMINATION OF CERTAIN DIURETICS IN PURE FORMS AND IN THEIR PHARMACEUTICAL FORMULATIONS Michael E. El-Kommos1, Ahmad A. Ahmad2, Hesham Salem3* and Mahmoud A. Omar3 1Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt 2Department of Organic Chemistry, Faculty of Science, Minia University, Minia, Egypt 3Department of Analytical Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt ﺘﻬﺎ ( ، ، ، ، ، ، ، ) . ﻋﻠﻰ ٥٠٠ . ٧٢٠ . ٤- - ٧- ﻟﺼﻔﻴﺎ ٤٧٠ . ، ٥٣٥ . Three Simple and selective spectrophotometric and spectrofluorimetric methods were developed for the quantitative determination of certain diuretics (bendroflumethiazide, benzthiazide, chlorthalidone, clopamide, hydrochlorothiazide, hydroflumethiazide, indapamide and xipamide) in pure forms as well as in their pharmaceutical formulations through their hydroxamate formation and subsequent complexation with iron (method I), reaction with potassium ferricyanide (method II) and ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ Received in 11/9/2005 & Accepted in 12/3/2006 * Corresponding author E-mail address: [email protected] Michael E. El-Kommos, et al. reaction with 4-chloro-7-nitrobenzofurazan (method III). The conditions for different reactions were studied and optimized. The methods have been validated and successfully applied to the analysis of bulk drugs and their tablets with good recoveries ranging from 97.93 (±1.46) to 100.6 (±1.75) for method I, 98.49 (±1.43) to 99.86 (±0.87) for method II, and 98.98 (±1.11) to 99.90 (±0.86) for method III. No interference was observed from common pharmaceutical adjuvants. The results obtained compare well with those of reported methods. INTRODUCTION used for assay of chlorthalidone.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]